Gilead-Backed Aspen Neuroscience Shares Decline 2% After US IPO
Open the sourceReported by Bloomberg, bloomberg.com, 30 October 2026, by Angel Adegbesan
50Impact 50 of 100, routine
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Muhabbit only has the headline for this one. The full report is at bloomberg.com.
Named in this story
Aspen Neuroscience Inc., Gilead